ProSiebenSat.1 Extends Partnership with SES
SES announced today a multi-year extension of its agreement with ProSiebenSat.1. Under the agreement, ProSiebenSat.1 will continue to distribute its programmes in Germany and Austria using SES’s satellites at its prime video neighbourhood of 19.2 degrees East. Additionally, ProSiebenSat.1 will integrate content from Joyn, its streaming platform in Germany, with SES’s HD+ TV App.
For the German market, the agreement extends ProSiebenSat.1’s satellite capacity and uplink services for the distribution of its HD channels. In addition, the HD+ contract between the two companies was expanded so that Joyn’s extensive library of series, shows, originals and exclusives will be integrated into SES’s HD+ TV app. This means that ProSiebenSat.1's HD channels will continue to be available via the HD+ platform, with additional Joyn content available for users of the HD+ TV app. Owned by ProSiebenSat.1, Joyn is a free streaming service for smart TVs and mobile devices with more than 7.6 million recent users.
In Austria, the agreement includes the extension of satellite capacity and uplink services for distribution of ProSiebenSat.1’s channels in both SD and HD quality.
"The new agreement with SES is important for viewers who receive our channels via HD+. Not only it secures the multi-year distribution of our linear HD channels via satellite, but soon the HD+ TV app viewers will have the opportunity to conveniently access the vast content of our streaming platform Joyn directly as part of the HD+ offering," said Nicole Agudo Berbel, Chief Distribution Officer at ProSiebenSat.1 and Managing Director at Joyn. “We are excited to further strengthen our successful partnership with SES with another forward-looking project.”
"ProSiebenSat.1’s compelling news, entertainment and sports content plays an integral part of the daily routine in many households in Germany and Austria. This extension underscores the importance of satellite in reliably delivering TV programming to the broadest audiences possible,” said Deepak Mathur, Global Head of Media at SES. “We are also excited to further expand the content selection of our hybrid, satellite and on-demand, HD+ TV App by incorporating Joyn’s diverse range of content offerings."
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous orbit fleet and medium earth orbit (GEO-MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227590226/en/
Contacts
For further information please contact:
Suzanne Ong
Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ENHERTU ® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy28.2.2025 15:00:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#ASCO24) Annual Meeting and pu
Radisys Expands Small Cell Portfolio with Qualcomm Dragonwing FSM200 Platform for FR1 and FR228.2.2025 15:00:00 EET | Press release
Radisys® Corporation, a global leader of open telecom solutions, announced the availability of its award-winning Connect RAN software on the Qualcomm Dragonwing™ FSM200 Platform for both FR1 and FR2. The solution leverages baseband and advanced Radio capabilities of the Dragonwing FSM200 platform to address high performance/capacity use cases with advanced features required in various market segments, including MNOs, enterprise, Fixed Wireless Access (FWA), private 5G, Industry 4.0 and home networks. Radisys Connect RAN software on the Qualcomm Dragonwing™ FSM100 platform is already globally deployed for various use cases. Radisys' Connect RAN 5G solution offers a comprehensive feature set, fully interoperable with a wide ecosystem and robust manageability support, enabling customers to deploy small cells in multiple verticals at reduced operational and capital expenses with a quick time-to-market. Highlights Radisys demonstrated continued leadership in mmWave RAN on Dragonwing FSM100
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO ® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations28.2.2025 14:22:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We are thrilled by the positive CHMP opinion in support of expanding the KAFTRIO in combination with ivacaftor indication to include all CF patients 2 years and older who make CFTR protein,” said Fosca De Iorio, M.D., Vice President, International Medical Affairs at Vertex. “If approved, thousands of additional patients across Europe will be eligible for a CFTR modulator, bringing us closer than ever to our goal of getting treatments that address the underlying cause of the disease to all people living with CF.” In the Eur
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order28.2.2025 14:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that (i) the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to the board of directors of SINOVAC and (ii) the Company’s Rights Agreement (also known as poison pill agreement) was invalid. Upon the receipt of the Order, SINOVAC has begun to implement the Judgment and the Order. As the Company's Rights Agreement is void, all the exchange shares issued pursuant to the Rights Agreement (the “Exchange Shares”), including 27,777,341 common shares and all 14,630,813 Convertible Series B Preferred Shares of SINOVAC, held by the 2019 Rights Exchange Trust, are void and will be cancelled. The
Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax28.2.2025 13:21:00 EET | Press release
Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status. Regarding the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) in second-line therapy (NCT06382168), the Data Management Committee (DMC) has approved the tolerability of all six patients in the Phase I (dose finding) portion of the Phase I/II study, and we are moving to the Phase II portion of the trial for efficacy testing as of today, on 28th Feb., 2025. We are pleased to inform that we already have multiple potential patients waiting to participate in the trial. Please take notice of our own innovative approach for miserable cancer patients and contact us. View source version on businesswire.com: https://www.businesswire.com/news/home/20250228414852/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom